Pre-exposure (PrEP)
Pre-exposure Prophylaxis (PrEP)
CROI 2013: Women's PrEP Trial Does Not Show HIV Risk Reduction [VIDEO]
- Details
- Category: HIV Prevention
- Published on Sunday, 24 March 2013 00:00
- Written by Gregory Fowler
Long-awaited results from the VOICE trial of post-exposure prophylaxis (PrEP) for women in Africa, presented at the recent 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta, was not able to show that daily oral tenofovir plus emtricitabine (the drugs in Truvada) could lower the risk of HIV acquisition.
CROI 2013: Maraviroc Does Not Prevent Immune Reconstitution Syndrome [VIDEO]
- Details
- Category: HIV Prevention
- Published on Sunday, 24 March 2013 00:00
- Written by Gregory Fowler
The CCR5 co-receptor blocker maraviroc (Selzentry) did not reduce the risk of developing immune reconstitution inflammatory syndrome (IRIS) after starting antiretroviral therapy (ART), according to study findings presented at the recent 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.
CROI 2013: Monthly Injectable and Tenofovir Vaginal Ring Protect Monkeys against Infection
- Details
- Category: HIV Prevention
- Published on Wednesday, 06 March 2013 00:00
- Written by Gus Cairns
A long-acting injectable integrase inhibitor (GSK1265744) protected male macaque monkeys from rectal infection with an HIV-like virus, while a vaginal ring containing tenofovir prevented infection of female monkeys, researchers reported at the this week at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.
New Advocacy Group Wants to Improve Feasibility of PrEP for U.S. Women
- Details
- Category: HIV Prevention
- Published on Wednesday, 20 March 2013 00:00
- Written by Anna Forbes
Following disappointing results from the VOICE trial released at the recent 20th Conference on Retroviruses and Opportunistic Infections (CROI) in Atlanta, a new U.S. Women and PrEP Working Group has called on the federal government to help American women use antiretroviral pre-exposure prophylaxis (PrEP) safely and effectively. But the AIDS Healthcare Foundation (AHF) responded by urging the Food and Drug Administration to rescind its approval of Truvada (tenofovir/emtricitabine) for HIV prevention.
CROI 2013: VOICE Trial's Disappointing Result Poses Big Questions for PrEP
- Details
- Category: HIV Prevention
- Published on Monday, 04 March 2013 00:00
- Written by Gus Cairns
The failure of one of the largest trials yet conducted of HIV drug-based prevention methods poses questions for how to turn vaginal microbicides and oral pre-exposure prophylaxis (PrEP) into methods people can actually use, the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta heard today.
More Articles...
- Truvada PrEP Demonstration Project Debuts in San Francisco
- ICAAC 2012: Novel NNRTI MK-1439 Shows Potent Activity, Distinct Resistance Profile
- Analysis Confirms Link Between PrEP Adherence and Reduced HIV Risk, Estimates Effective Dosing
- ICAAC 2012: Long-acting Integrase Inhibitor S/GSK1265744 Active Against HIV Subtypes
Web Design and Development by